Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genetics Generation Advancement's EBIT per Share for the
three
months ended in Dec. 2025 was NT$0.54.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was NT$1.05.
During the past 12 months, the average EBIT per Share Growth Rate of Genetics Generation Advancement was -74.10% per year.
During the past 3 years, the average EBIT per Share Growth Rate was -14.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Genetics Generation Advancement's EBIT per Share or its related term are showing as below:
ROCO:4160'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -14.9 Med: 20.45 Max: 43.3
Current: -14.9
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Genetics Generation Advancement was 43.30% per year. The lowest was -14.90% per year. And the median was 20.45% per year.
ROCO:4160's 3-Year EBIT Growth Rate is ranked worse than 80.61% of 165
companies
in the Medical Diagnostics & Research industry
Industry Median: 13.2
vs ROCO:4160: -14.90
Genetics Generation Advancement (ROCO:4160) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Genetics Generation Advancement EBIT per Share Related Terms
Genetics Generation Advancement EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genetics Generation Advancement EBIT per Share Chart
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$1.05
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genetics Generation Advancement (ROCO:4160) has a EBIT per Share of NT$1.05 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Genetics Generation Advancement and its competitors. According to the industry distribution chart, Genetics Generation Advancement ranks #133 out of 165 companies in the Medical Diagnostics & Research industry, placing it in the top 80.6%.
Is Genetics Generation Advancement's EBIT per Share too high?
Genetics Generation Advancement's current EBIT per Share is NT$1.05. Based on the distribution chart, Genetics Generation Advancement ranks #133 out of 165 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Genetics Generation Advancement has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genetics Generation Advancement's EBIT per Share compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Genetics Generation Advancement ranks #133 out of 165 companies for EBIT per Share. This places Genetics Generation Advancement in the lower half of its industry. The industry median EBIT per Share is 13.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Diagnostics & Research company?
The median EBIT per Share among Medical Diagnostics & Research companies is 13.20, based on 165 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Genetics Generation Advancement and its competitors. For the Medical Diagnostics & Research industry, the median EBIT per Share is 13.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genetics Generation Advancement's current EBIT per Share is NT$1.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetics Generation Advancement stock overvalued right now?
Based on GuruFocus' analysis, Genetics Generation Advancement (ROCO:4160) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$51.38, compared to a current price of NT$39.90 — trading 22.3% below its estimated fair value. The current EBIT per Share is NT$1.05. Genetics Generation Advancement's overall GF Score™ is 71/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Genetics Generation Advancement (ROCO:4160), the current EBIT per Share is NT$1.05 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genetics Generation Advancement (ROCO:4160) Overvalued in 2026?
Based on GuruFocus' analysis, Genetics Generation Advancement stock appears to be undervalued.
The current stock price of NT$39.90 is trading 22.3% below its estimated GF Value™ of NT$51.38.
GuruFocus considers Genetics Generation Advancement to be Modestly Undervalued.
Key valuation signals for ROCO:4160:
EBIT per Share: NT$1.05
GF Value™: NT$51.38 vs. price of NT$39.90 (22.3% below fair value)
No single metric tells the full story. See the ROCO:4160 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genetics Generation Advancement Business Description
Genetics Generation Advancement Corp is a Taiwan based company specialized in genetic testing and scientific information. It is engaged in providing services for the detection of genetic defects and prevention in newborns. Their main services include amniotic fluid chromosome chip screening, pre-implantation genetic diagnosis, and Molecular DNA testing diagnostics. The company is focused on the majority of areas of maternal precision medicine, pediatric disease diagnosis, drug-associated diagnosis, non-invasive cancer detection, and precise health management. The business units of the company are the Genetic Testing Unit and Informatics business unit.
71GF Score
Get the complete analysis for ROCO:4160
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4160 has been successfully added to your 
